{"id":"W2086572083","doi":"10.1212/wnl.0b013e3181c67808","title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","year":2009,"lang":"en","type":"letter","venue":"Neurology","topic":"Alzheimer's disease research and treatments","field":"Medicine","cited_by":739,"is_retracted":false,"has_abstract":true,"ca_institutions":"Women's Health Research Institute","funders":"National Center for Research Resources; National Institute of Neurological Disorders and Stroke; National Institute of Mental Health; National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute on Aging; National Institute on Alcohol Abuse and Alcoholism; U.S. Public Health Service; National Institute for Health and Care Research; Pfizer","keywords":"Medicine; Internal medicine; Asymptomatic; Placebo; Cognitive decline; Dementia; Population; Disease; Gastroenterology; Clinical endpoint; Oncology; Pathology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001658382,0.001296887,0.00144932,0.0003664239,0.0003612722,0.0007359003,0.0007031011,0.0007682369,0.002584051],"category_scores_gemma":[0.001259695,0.0003470112,0.0008484222,0.0002147274,0.0005020538,0.0004987524,0.0002776834,0.002017705,0.0005013573],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005103757,"about_ca_system_score_gemma":0.0009832507,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004766645,"about_ca_topic_score_gemma":0.00126764,"domain_scores_codex":[0.9996054,0.0001954317,0.00002310012,0.00005941421,0.00005604256,0.00006073572],"domain_scores_gemma":[0.9992761,0.0001452896,0.0001593665,0.00006388185,0.0000809703,0.000274348],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8355588,0.0488546,0.004225728,0.0007323904,0.00123092,0.000207729,0.0003187284,0.001100604,0.0236464,0.0002006126,0.001892642,0.08203088],"study_design_scores_gemma":[0.7948433,0.1922346,0.008173824,0.00003605782,0.0003874246,0.0001735,0.0000281581,0.0006602317,0.001896921,0.0001810189,0.001364626,0.00002025456],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966745,0.0009473712,0.0002306619,0.0001788993,0.00005201164,0.000952101,0.000210339,0.00003607127,0.0007179314],"genre_scores_gemma":[0.9933061,0.001086391,0.00142863,0.0004620546,0.000160462,0.001512438,0.0006778518,0.00001090605,0.001355068],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002584051,"threshold_uncertainty_score":0.008770466,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06927806411358578,"score_gpt":0.3671225997386713,"score_spread":0.2978445356250856,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}